Market incentives and pharmaceutical innovation

Journal of Health Economics

Volumn 27, Issue 4, 2008, Pages 1060-1077

  Yin, Wesley ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Health policy; Pharmaceutical innovation; Technological change

Indexed keywords

NEW DRUG;

DISEASE PREVALENCE; DRUG DEVELOPMENT; HEALTH POLICY; INNOVATION; MARKET; PHARMACEUTICAL INDUSTRY; RARITY; TAX INCENTIVE;

ACT; ARTICLE; DRUG MARKETING; DRUG RESEARCH; HEALTH CARE POLICY; INVESTMENT; MARKET; ORPHAN DRUG ACT; PREVALENCE; PRIVATE PRACTICE; RARE DISEASE; TAX; TECHNOLOGY;

DRUG INDUSTRY; HEALTH POLICY; MOTIVATION; ORPHAN DRUG PRODUCTION; RESEARCH; UNITED STATES;

EID: 44649165634     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2008.01.002     Document Type: Article

References (44)

1. Acemoglu D., and Linn J. Market size in innovation: theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics 119 3 (2004) 1049-1090
2. Altman R.D., Bloch D.A., Hochberg M.C., and Murphy W.A. Prevalence of pelvic Paget's disease of bone in the United States. Journal of Bone and Mineral Research 15 3 (March) (2000) 461-465 (Medline 10750560)
3. Anderson D.W., et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Annals of Neurology 31 3 (March) (1992) 333-336 (Medline 1637140)
4. Asbury C. Orphan Drugs: Medical vs Market Value (1986), Lexington Books, Lexington, MA
5. Aspinall M.G., and Hamermesh R.G. Realizing the promise of personalized medicine. Harvard Business Review 85 10 (2007)
6. Cameron A.C., and Trivedi P.K. Regression Analysis of Count Data (1998), Cambridge University Press
7. Chamberlain E. The Theory of Monopolistic Competition (1931), Harvard University Press, Cambridge, MA
8. Collins F., Green E., et al. A vision for the future of genomics research. Nature 422 (2003) 835-847
9. Couzin J. To what extent are genetic variation and personal health linked?. Science 309 5731 (2005) 81
10. Curhan G.C., et al. Epidemiology of interstitial cystitis: a population based study. Journal of Urology 161 2 (February) (1999) 549-552 (Medline 9915446)
11. DiMasi J., Hansen R., et al. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22 (2003) 151-185
12. Division of Oral Medicine, University of Minnesota, 1999. Sjogren's syndrome, Quintessence International, 30 (10 (October)), 689-699 (Medline 10765853).
13. Dixit A., and Stiglitz J. Monopolistic competition and optimum product diversity. American Economic Review 67 (1977) 297-308
14. Finkelstein A. Static and dynamic effect of health policy: evidence from the vaccine industry. Quarterly Journal of Economics 119 2 (2004) 527-564
15. Garrison L.P., and Austin M.J. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs 25 5 (2006) 1281-1290
16. General Accounting Office. The Research Tax Credit Has Stimulated Some Additional Research (1989), Government Printing Office, DC
17. Grabowski H. Encouraging the development of new vaccines. Health Affairs 24 3 (2005) 697-700
18. Haffner M.E., Whitley J., et al. Two decades of orphan product development. Nature Reviews Drug Discovery 1 (2002) 821-825
19. Hall B. R&D tax policy during the eighties: success or failure?. Tax Policy and the Economy 7 (1993) 1-36
20. Hall B. The financing of research and development. Oxford Review of Economic Policy 18 1 (2002) 35-51
21. Hall B., and Van Reenen J. How effective are fiscal incentives for R&D? A review of the evidence. Research Policy 29 4-5 (2000) 449-470
22. Hausman J., Hall B., et al. Econometric models for count data with application topatents-R&D relationship. Econometrica 52 (1984) 909-938
23. Hilts, P., 2003. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation, Knopf.
24. Hochberg M.C., et al. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus 4 6 (December) (1995) 454-456 (Medline 8749567)
25. Hotelling H. Stability in competition. Economic Journal 39 (1929) 41-57
26. House of Representatives Subcommittee Report. Preliminary Report of the Survey on the Drugs for Rare Diseases. Subcommittee on the Health and the Environment (1982), Government Printing Office, DC
27. Kaspar R.L. Challenges in developing therapies for rare diseases including pachyonychia congenita. Journal of Investigative Dermatology Symposium Proceedings 10 (2005) 62-66
28. Kremer M. Creating markets for new vaccines. Part I. Rationale. In: Jaffe A.B., Lerner J., and Stern S. (Eds). Innovation Policy and the Economy 1 (2001), MIT Press
29. Kremer M. Creating markets for new vaccines. Part I. Design Issues. In: Adam B.J., Josh L., and Scott S. (Eds). Innovation Policy and the Economy 1 (2001), MIT Press
30. Lichtenberg, F., Waldfogel, J., 2003. Does misery love company? evidence from pharmaceutical markets before and after the orphan drug act. NBER working paper No. 9750.
31. Loftus E.V., Schoenfeld P., and Sandborn W.J. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Alimentary Pharmacology and Therapeutics 16 1 (January) (2002) 51-60 (Medline 11856078)
32. Mansfield, E., 1986. The R&D tax credit and other technology policy issues. American Economic Review Papers and Proceedings 1976; 190-194.
33. McCutchen W. Estimating the impact of the R&D tax credit on strategic groups in the pharmaceutical industry. Research Policy 22 (1993) 337-351
34. Newell R., Jaffee A., et al. The induced innovation hypothesis and energy-saving technological change. Quarterly Journal of Economics 114 3 (1999) 907-940
35. Office of Management and Budget, 2007. Analytical perspectives, budget of the United States Government, Fiscal Year 2008.
36. Office of Technological Assessment. The Effectiveness of the Research and Experimentation Tax Credits (1993), Government Printing Office, DC
37. Riordan M. Monopolistic competition with experience goods. Quarterly Journal of Economics 90 (1986) 629-650
38. Rohde D.D. The orphan drug act: an engine of innovation? At what cost?. Food and Drug Law Journal 55 1 (2000) 125-143
39. Salop S. Monopolistic competition with outside goods. Bell Journal of Economics 10 1 (1979) 141-156
40. Spence A.M. Product selection fixed costs and monopolistic competition. Review of Economic Studies 43 (1976) 217-236
41. Trivedi H.S., Pang M.M., Campbell A., and Saab P. Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. American Journal of Kidney Diseases 39 4 (April) (2002) 721-729 (Medline 11920337)
42. Wooldridge. quasi-likelihood methods for count data. In: Pesaran M.H., and Schmidt P. (Eds). Handbook of Applied Econometrics 2 (1997), Blackwell, Oxford 352-406
43. Wooldridge. Distribution-free estimation of some non-linear panel data models. Journal of Econometrics 90 (1999) 77-97
44. Xue J.L., Ma J.Z., Louis T.A., and Collins A.J. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. Journal of the American Society of Nephrology 12 12 (December) (2001) 2753-2758 (Medline 11729245)